Abstract
Lung cancer is the leading cause of cancer-related death in the world. PD-1 is a member of the CD28 family expressed on the surface of a variety of immune cells. PD-L1, one of PD-1 ligands, plays a pivotal role in the ability of tumor cells to evade the host immune system. A recent study showed that signaling via mutant EGFR in lung tumor cells upregulates directly tumor PD-L1 expression. In this review, the clinical significance of the PD-1/PD-L1 pathway in immunotherapy for non-small-cell lung cancer (NSCLC) and the relevance to targeted therapy were summarized. Key words: Carcinoma, non-small-cell lung; Programmed death-1; Programmed death ligand-1; Epithelial growth factor receptor; Immunotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
